Atlas Trials

Pre-transplant Purging and Post-transplant MRD-guided Maintenance Therapy With Elranatamab in Patients With High-risk Multiple Myeloma

Clinical trial NCT06207799 · RECRUITING

Trial details

NCT number
NCT06207799
Sponsor
M.D. Anderson Cancer Center
Status
RECRUITING
Phase
Phase 2
Study type
INTERVENTIONAL
Multiple MyelomaPost-transplant MRD-guided Maintenance TherapyPre-transplant Purging
Start date
2024-07-17
Primary completion
2029-12-31
Enrollment
40

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.